Stoq 10 mg (Lafutidine)

Adult dose

1. Short-term treatment of gastric ulcers The usual dose is 10mg of lafutidine per dose, administered orally twice daily in the morning and at bedtime. In clinical trials with treatment for up to 8 weeks, most patients healed within 8 weeks, although the healing period may vary in some patients. 2. Short-term treatment of duodenal ulcers The usual dose is 10mg of lafutidine per dose, administered orally twice daily in the morning and at bedtime. In clinical trials with treatment for up to 6 weeks, most patients healed within 6 weeks, although the healing period may vary in some patients. 3. Improvement of gastric mucosal lesions in acute and chronic gastritis The usual dose is 10mg of lafutidine once daily, administered orally at bedtime. In clinical trials with treatment for up to 2 weeks, most patients healed within 2 weeks, although the healing period may vary in some patients. 4. Combination antibiotic therapy for patients with peptic ulcers infected with Helicobacter pylori Administer 20mg of lafutidine, 500mg of clarithromycin, and 1000mg of amoxicillin twice daily for 7 days or 14 days. 5. Premedication before anesthesia The usual dose is 10mg of lafutidine per dose, administered orally twice (at bedtime on the day before surgery and 2 hours before anesthesia on the day of surgery). 6. Treatment of reflux esophagitis Administer 10mg of lafutidine per dose orally twice daily.

This medication should not be used in patients with hypersensitivity to any component of this medication. Moreover, this medication contains lactose and should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. Caution should be taken when administering this medication to patients with a history of drug hypersensitivity, patients with poor liver function, patients with decreased kidney function, patients undergoing dialysis, and the elderly. This medication may rarely cause severe allergic reactions such as anaphylaxis, so if symptoms such as facial pallor, decreased blood pressure, generalized flushing, or difficulty breathing occur, administration should be stopped immediately and appropriate treatment should be received. Liver function abnormalities or jaundice may occur, so liver function tests should be conducted regularly, and if abnormalities are found, administration should be stopped. Blood disorders such as agranulocytosis or thrombocytopenia may occur, so if symptoms such as pharyngodynia, generalized malaise, or fever appear, the medication should be stopped immediately and a consultation with a physician is necessary. Additionally, rare abnormal reactions such as skin rash, seizures, interstitial nephritis, and heart block have been reported, so close observation is required in case of symptom development. Gastrointestinal symptoms may include constipation, diarrhea, nausea, vomiting, abdominal bloating, and loss of appetite, while central nervous system symptoms may include headache, insomnia, drowsiness, and dizziness. Elderly patients may have decreased physical function, so careful adjustment of dosage and administration intervals should be observed, and their condition should be closely monitored. For patients undergoing dialysis, blood drug concentrations may increase, so administration should start carefully from a low dose. Pregnant women or women of childbearing potential should use it only when the therapeutic benefits outweigh the risks under a doctor's judgment, and it is advisable not to administer it to breastfeeding women as it may be excreted in breast milk. The safety for pediatric patients has not yet been established, so caution is needed for use. This medication should be kept out of reach of children and stored in its original container to prevent misuse or deterioration in quality. Finally, if malignancy is suspected, appropriate tests should be conducted for early diagnosis, and if confirmed as malignant gastric cancer, administration of this medication should be stopped.

• Shock
• symptoms of anaphylaxis
• facial pallor
• hypotension
• generalized rash
• dyspnea
• liver dysfunction
• jaundice
• agranulocytosis
• pharyngitis

This medication may be sensitive to air or moisture, so it should be kept in a tightly sealed container. It is recommended to store the medication at room temperature between 1°C and 30°C, away from excessive heat or cold.

Appearance

White, round film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle